Femtech is transforming women’s health by delivering innovative software solutions across fertility, menstrual health, pre-pregnancy, postpartum care and menopause. As these apps and devices collect sensitive personal health data and offer medical insights, the distinction between lifestyle tracking tools and regulated medical technologies can become blurred. When wellness technologies transition into the realm of healthcare, it is crucial to understand how femtech fits within medical device regulatory frameworks. Identifying whether, and where, your software falls under these regulations is essential for ensuring smooth market entry and maintaining ongoing compliance.
When does software become a medical device?
Determining when femtech software qualifies as a medical device is a critical regulatory consideration. According to the Australian Therapeutic Goods Administration (TGA), a medical device includes any software intended for use in the diagnosis, prevention, monitoring, treatment, or management of a disease or medical condition. All such devices must be included on the Australian Register of Therapeutic Goods (ARTG).
The TGA does not regulate health and lifestyle apps that do not meet the definition of a medical device.
However, if software performs functions beyond simple lifestyle or wellness tracking (such as analysing symptoms, providing clinical recommendations, or influencing treatment decisions), it is likely to be classified as a medical device. For example, an app that merely tracks menstrual cycles for convenience may not require regulation, whereas one that predicts ovulation with medical accuracy to aid fertility treatment would fall under medical device regulation. Similarly, the TGA will often view apps and software for monitoring baby movements or kicks during pregnancy as a medical device which must be included on the ARTG (on the basis that they are intended to prevent foetal harm through monitoring foetal movement).
If a product constitutes a medical device, it will be classified under the TGA. The TGA classifies medical devices into different risk categories based on their intended purpose and potential risk to patients, from Class I (low risk) to Class III (high risk). Femtech software often falls within the lower classification range, but higher-risk applications (such as those providing diagnostic or therapeutic functions) may be subject to stricter controls.
A medical device’s classification status can also trigger further TGA obligations including:
- product registration – as noted above, medical devices must be included on the ARTG before they can be supplied in Australia. This process involves submitting detailed information about the product, including its intended use, technical specifications, and evidence supporting its safety and performance;
- conformity assessment – manufacturers must demonstrate conformity with relevant regulatory requirements through an appropriate conformity assessment;
- compliance with safety and performance standards – femtech devices must comply with the TGA’s essential principles, ensuring that they are safe, effective and perform as intended. This includes rigorous testing, risk management, and quality assurance throughout the product lifecycle; and
- post-market monitoring – after market entry, ongoing responsibilities include monitoring the device’s performance, reporting adverse events or incidents to the TGA, and complying with audits or inspections as necessary.
Data is a double-edged sword
Femtech apps often collect highly sensitive health information, such as menstrual cycles, hormonal levels or pregnancy information. This data is vital not only for enhancing user experience but also for defining the software’s intended use and regulatory classification. Navigating compliance with the regulatory landscape is crucial to avoid legal penalties and maintain user trust.
Other key legal considerations include:
- data protection – complying with the Australian Privacy Act and the Australian Privacy Principles (APPs), which regulate the collection, use, and storage of sensitive health data, alongside international standards like GDPR when serving global users;
- artificial intelligence – evaluating how AI-driven tools align with emerging Australian AI governance frameworks;
- corporate – navigating early-stage funding landscapes including grants, venture capital, and government support programs;
- IP licensing – managing intellectual property rights and licensing agreements, particularly in collaboration with universities and research institutions; and
- patents – monitoring patent trends to protect innovations while avoiding infringement risks.
By addressing these areas thoughtfully, femtech developers can better position themselves for success in Australia’s evolving healthcare and regulatory environment.
Key considerations for developing femtech in Australia
If you are developing or using femtech in Australia, here are some key points to keep in mind:
- early regulatory classification assessment – is your product likely to be a medical device? If yes, plan for evidence, registration, compliance early rather than after product launch;
- privacy by design – given the sensitivity of data, build in strong privacy & security features; be clear with users what data is collected, how it is used/shared; ensure compliance with APPs;
- transparency of claims – avoid overstating what the tech can do and ensure claims are supported by data and/or clinical trials;
- stay on top of reforms – the law is changing in privacy, AI, and digital health. What’s legal today might be more tightly regulated in a few years; and
- local compliance – even if product is developed elsewhere, ensure it meets Australian laws (including device standards, privacy and advertising).
Successfully navigating femtech regulation in Australia requires clear differentiation between wellness apps and medical devices, careful risk assessment, and proactive compliance with data and regulatory frameworks. Engaging legal expertise early helps developers to build femtech solutions that are not only compliant but also safe, effective, and trusted by users, enabling developers to unlock the transformative potential of femtech and advancing women’s health innovation.
